Amprenavir-VX-478-DataSheet-生命科學(xué)試劑-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEAmprenavirCat. No.: HY-17430CAS No.: 161814-49-9Synonyms: VX-478分式: CHNOS分量: 505.63作靶點(diǎn): HIV; HIV Protease作通路: Anti-infection; Metabolic Enzyme/Protease儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外

2、實(shí)驗(yàn) DMSO : 100 mg/mL (197.77 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲(chǔ)備液1 mM 1.9777 mL 9.8887 mL 19.7773 mL5 mM 0.3955 mL 1.9777 mL 3.9555 mL10 mM 0.1978 mL 0.9889 mL 1.9777 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲(chǔ)備液，并請(qǐng)注意儲(chǔ)備液的保存式和期限。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥式選擇適當(dāng)?shù)娜芙獍?，配制前?qǐng)先配制澄清

3、的儲(chǔ)備液，再依次添加助溶劑(為保證實(shí)驗(yàn)結(jié)果的可靠性，體內(nèi)實(shí)驗(yàn)的作液，建議您現(xiàn)現(xiàn)配，當(dāng)天使；澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；以下溶劑前的百分 指該溶劑在您配制終溶液中的體積占)：1. 請(qǐng)依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (4.94 mM); Clear solution2. 請(qǐng)依序添加每種溶劑： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (4.94 mM); Clear solution1/2 Maste

4、r of Small Molecules 您邊的抑制劑師www.MedChemE3. 請(qǐng)依序添加每種溶劑： 10% DMSO 90% corn oilSolubility: 2.5 mg/mL (4.94 mM); Clear solutionBIOLOGICAL ACTIVITY物活性 Amprenavir (VX-478)HIV蛋酶抑制劑，Ki為0.6 nM。IC50 & Target IC50 Value: 0.6 nM (Ki); Against wild-type clinical HIV isolates:14.6 +/- 12.5 ng/mL (mean +/- SD) 1.Ta

5、rget:HIV protease體外研究 Amprenavir has an enzyme inhibition constant (Ki = 0.6 nM) that falls within the Ki range of the otherprotease inhibitors. Amprenavirs in vitro 50% inhibitory concentration (IC50) against wild-type clinical HIVisolates is 14.6 +/- 12.5 ng/mL (mean +/- SD) 1. Amprenavir had dire

6、ct inhibitory effects on invasion of Huh-7 hepatocarcinoma cell lines, inhibiting MMP proteolytic activation 2.體內(nèi)研究 Amprenavir was able to promote regression of hepatocarcinoma growth in vivo by anti-angiogenetic andoverall anti-tumor activities, independently by PI3K/AKT related pathways that at to

7、day is one of the moresuggestive hypothesis to explain the anti-tumor effects of the different protease inhibitors 2. Amprenavirefficiently activated PXR and induced PXR target gene expression in vitro and in vivo. Short-term exposureto amprenavirsignificantly increased plasma total cholesterol and

8、atherogenic low-density lipoproteincholesterol levels in wild-type mice, but not in PXR-deficient mice 3. Amprenavir has been approved foradults and children; the recommended capsule doses are 1200 mg twice daily for adults and 20 mg/kg twicedaily or 15 mg/kg 3 times daily for children 13 years of a

9、ge or adolescents 50 kg 1.REFERENCES1. Sadler BM, Stein DS. Clinical pharmacology and pharmacokinetics of amprenavir. Ann Pharmacother. 2002 Jan;36(1):102-18.2. Esposito V, Verdina A, Manente L, Amprenavir inhibits the migration in human hepatocarcinoma cell and the growth of xenografts. J CellPhysiol. 2013 Mar;228(3):640-5.3. Helsley RN, Sui Y, Ai N, Pregnane X Receptor Mediates Dyslipidemia Induced by the HIV Protease Inhibitor Amprenavir in Mice. MolPharmacol. 2013 Jun;83(6):1190-9.McePdfHeightCaution: Product has not been fully validated